PEGS Boston - Protein Engineering Summit

May 4-8, 2020
Boston, MA, USA

Meet Genedata experts at PEGS in Boston, MA, USA.

Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, stratification of clinical trial subjects, and quality control of biologicals.

To get more information about Genedata solutions, please contact

Recommended Oral Presentations

In-Depth Peptide Mapping Profiling of Multispecific Antibodies using Genedata Expressionist
Soraya Hoelper, PhD, Lab Head Mass Spectrometry, Protein Therapeutics, R&D Biologics Germany, Sanofi-Aventis Deutschland GmbH
Arnd Brandenburg, PhD, Head, Professional Services, Genedata Expressionist, Genedata

Characterization for Novel Biotherapeutics Session
Tuesday, May 5 | 12:255 pm - 1:25 pm

At Sanofi, we use peptide mapping to perform deep characterization of innovative multispecific biotherapeutics. We developed a custom data processing workflow that enables us to extract the maximum amount of molecular information from our biotherapeutic candidate molecules and created a knowledge base that allows us to leverage the insights gained throughout a molecule’s lifecycle for future analyses and development.

Dealing with the Combinatorial Complexity of Protein Engineering: Bi- and Multi-specifics, TCRs and CAR Ts
Amanda Fitzgerald, Ph.D., Senior Scientific Consultant, Biologics, Genedata Inc.

Engineering Bispecific Antibodies Session
Thursday, May 7 | 3:20 pm - 3:50 pm

We present a new technology platform to fully automate both molecular design, as well as the integrated assessment of potency, efficacy, and developability profiling of large panels of bispecific candidates. We will present use cases showing how the platform allows for the systematic cloning, expression, purification, and characterization of complex multi-specific, CAR T and TCR modalities, with a focus on immuno-oncology applications.

Platformization of Multi-Specific Protein Engineering
Dietmar Hoffmann, Ph.D., Head of Molecular Expression and Screening Technologies, Biologics Research US, Sanofi

Engineering Bispecific Antibodies Session
Friday, May 8 | 9:35 am - 10:05 am

The success rate to identify a multi-specific lead molecule (e.g. a tri-specific antibody) increases with the number of variants tested. Therefore, systematic screening of a large panel of multi-specific variants in a high throughput approach is critical to identify candidates with drug like properties early in the discovery process. We have automated both the molecular biology and the protein production increasing our capability for medium-scale production of multi-specific antibodies facilitating more functional and developability assays.